Tag: prescription drug costs

A new federal enforcement deadline is set to reshape access to some of the country’s most in-demand weight-loss drugs. Starting May 22, the U.S. Food and Drug Administration (FDA) will prohibit most pharmacies and providers from producing or distributing compounded versions of GLP-1 medications semaglutide and tirzepatide, active ingredients in blockbuster drugs including Ozempic, Wegovy, Mounjaro, and Zepbound.

California Gov. Gavin Newsom is reviving efforts to regulate the powerful and often opaque intermediaries at the center of the prescription drug supply chain. In a proposal unveiled as part of his revised May budget, Newsom calls for stringent oversight of pharmacy benefit managers (PBMs), companies he says are driving up patient costs.